Refine your search

Clear

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa: Phase 2 Double-Blinded to Open-Label Study, up to 60 weeks long. Oral medication, Males/Females 18-75 years old with Hidradenitis Suppurativa (HS) for at least 3 months Hidradenitis Suppurativa (HS), is a long-lasting, inflammatory skin condition. HS is characterized by lesions that can be found most commonly in the groin, armpits, and buttocks. These lesions are very painful and can drain and cause scarring. The purpose of this study is to find out if the study drug, INCB054707 can help treat HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04476043
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
HS diagnosis for at least 3 months
HS lesions in at least 2 different areas
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for HS are not allowed; coordinator will discuss specific treatments
Positive test results for HIV, hepatitis B, or hepatitis C
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA